SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC)
Autor: | J. Lambea, J. J. Garcia, B. Pérez-Valderrama, Á. Rodríguez Sánchez, M.T. Abad Villar, Jose-Luis Gonzalez-Larriba, E.M. Fernandez Parra, J.A. Arranz Arija, E. Gallardo Diaz, Javier Cassinello, J.L. Puertas Álvarez, O. Etxaniz Ulazia, J.A. Virizuela Echaburu, M. Constenla Figueiras, M.J. Mendez Vidal, A. Pinto Marin, J.J. Tafalla García, C. Maximiano Alonso, F.J. Vazquez Mazon, J.C. Villa Guzman |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty Everolimus business.industry First line Hematology Axitinib Pazopanib 03 medical and health sciences 0302 clinical medicine Second line Internal medicine Medicine Metastatic renal carcinoma 030212 general & internal medicine business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Annals of Oncology. 28:v313 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |